This medical educational webinar is intended for healthcare professionals only to communicate clinical trial updates in the EMPOWER program, including the EMPA-KIDNEY trial. Empagliflozin is currently not indicated for the treatment of chronic kidney disease. Please refer to the local product information for the current indication in your country.